|
122 Companies |
|
161 Products |
|
161 Products |
|
116 Mechanisms of Action |
|
12 Trials |
|
2436 News |
|
| «12345678910111213...4950» |
- | Trial completion: HIV Risk Reduction in Youth in the Bahamas (clinicaltrials.gov) - Nov 7, 2017
P=N/A, N=1360, Completed, Sponsor: Wayne State University
Active, not recruiting --> Completed
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: QuaDar: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (clinicaltrials.gov) - Nov 6, 2017
P4, N=10, Completed, Sponsor: University of British Columbia
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Enrollment change: ANRS CO16: Cohort of HIV Associated Lymphomas (clinicaltrials.gov) - Nov 6, 2017
P=N/A, N=205, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=400 --> 205
- | Enrollment change, Trial termination: Pilot Study of Diflunisal in HIV-infected Adults (clinicaltrials.gov) - Oct 27, 2017
P4, N=8, Terminated, Sponsor: University of British Columbia
Active, not recruiting --> Completed | N=400 --> 205 N=20 --> 8 | Suspended --> Terminated; Insufficient enrollment.
- | Trial completion, HEOR: Medical Marijuana Use in HIV+ Patients Prospective Cohort Study (clinicaltrials.gov) - Oct 26, 2017
P=N/A, N=150, Completed, Sponsor: Wayne State University
N=20 --> 8 | Suspended --> Terminated; Insufficient enrollment. Active, not recruiting --> Completed
- ||| Tivicay (dolutegravir) / ViiV Healthcare
Trial completion: DOL-ART: A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (clinicaltrials.gov) - Oct 25, 2017
P=N/A, N=411, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment closed, Trial primary completion date: TLCIDU Kenya: Testing and Linkage to Care for Injecting Drug Users in Kenya (clinicaltrials.gov) - Oct 20, 2017
P=N/A, N=8800, Active, not recruiting, Sponsor: Yale University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Apr 2018
- | Mycobutin (rifabutin) / Pfizer, Lupin, Isentress (raltegravir) / Merck (MSD)
Trial completion: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV (clinicaltrials.gov) - Oct 19, 2017
P2b, N=71, Completed, Sponsor: AIDS Clinical Trials Group
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Apr 2018 Active, not recruiting --> Completed
- | Trial completion: PERTH: Postprandial Endothelial Dysfunction After a High-Fat Meal in HIV-infected Men (clinicaltrials.gov) - Oct 12, 2017
P=N/A, N=50, Completed, Sponsor: Tufts University
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| stavudine / Generic mfg., tenofovir disoproxil fumarate / Generic mfg., zidovudine / Generic mfg.
Trial completion: Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children (clinicaltrials.gov) - Oct 6, 2017
P3, N=97, Completed, Sponsor: Gilead Sciences
Recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment closed, Trial initiation date, Trial primary completion date, IO biomarker: MicroVIH: Randomized Placebo-controlled Pilot Trial of Prebiotics+Glutamine in HIV Infection (clinicaltrials.gov) - Oct 6, 2017
P1/2, N=45, Active, not recruiting, Sponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Active, not recruiting --> Completed Completed --> Active, not recruiting | Initiation date: Jun 2011 --> Jan 2017 | Trial primary completion date: Aug 2013 --> Jun 2018
- | Trial completion: Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS (clinicaltrials.gov) - Oct 5, 2017
P=N/A, N=82, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Completed --> Active, not recruiting | Initiation date: Jun 2011 --> Jan 2017 | Trial primary completion date: Aug 2013 --> Jun 2018 Recruiting --> Completed
- Phase classification, Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: The Effect of Probiotics in HIV-1 Infection (clinicaltrials.gov) - Sep 28, 2017
P=N/A, N=32, Completed, Sponsor: Oslo University Hospital
Recruiting --> Completed Phase classification: P2 --> P=N/A | N=100 --> 32 | Trial primary completion date: Jun 2012 --> Apr 2013
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Enrollment closed: TRIUMPH: Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (clinicaltrials.gov) - Sep 27, 2017
P=N/A, N=403, Active, not recruiting, Sponsor: ViiV Healthcare
Phase classification: P2 --> P=N/A | N=100 --> 32 | Trial primary completion date: Jun 2012 --> Apr 2013 Recruiting --> Active, not recruiting
- | Eyevinal (ibudilast) / MediciNova
Enrollment closed, Trial primary completion date: IBUD ph II: Trial of Ibudilast for Methamphetamine Dependence (clinicaltrials.gov) - Sep 25, 2017
P2, N=140, Active, not recruiting, Sponsor: University of California, Los Angeles
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017
- | metformin / Generic mfg.
Trial suspension: Improving Fibrosis Outcomes With Metformin (clinicaltrials.gov) - Sep 25, 2017
P2, N=60, Suspended, Sponsor: Ottawa Hospital Research Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017 Not yet recruiting --> Suspended
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) - Sep 20, 2017
P2, N=279, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Suspended Active, not recruiting --> Completed
- | carboplatin / Generic mfg., pemetrexed / Generic mfg.
Trial completion, Metastases: CHIVA: Chemotherapy for Lung Cancer in HIV-positive Patients (clinicaltrials.gov) - Sep 20, 2017
P2, N=62, Completed, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial completion: Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults (clinicaltrials.gov) - Sep 13, 2017
P3, N=55, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Phase classification: Prospective Epidemiological Study Of The Prevalence Of HLA-B*5701 (clinicaltrials.gov) - Sep 11, 2017
P=N/A, N=1569, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Phase classification: P4 --> P=N/A
- | Trial completion, Enrollment change, Trial primary completion date: Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) (clinicaltrials.gov) - Sep 11, 2017
P=N/A, N=21, Completed, Sponsor: University of Nebraska
Phase classification: P4 --> P=N/A Recruiting --> Completed | N=40 --> 21 | Trial primary completion date: Feb 2011 --> Dec 2014
- | Trial completion: Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults (clinicaltrials.gov) - Sep 8, 2017
P1, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | N=40 --> 21 | Trial primary completion date: Feb 2011 --> Dec 2014 Active, not recruiting --> Completed
- |||| Rukobia (fostemsavir) / ViiV Healthcare
Trial completion, Trial primary completion date: HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections (clinicaltrials.gov) - Sep 7, 2017
P2b, N=246, Completed, Sponsor: ViiV Healthcare
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> May 2017
- | Phase classification: Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications (clinicaltrials.gov) - Sep 5, 2017
P=N/A, N=56, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> May 2017 Phase classification: P2 --> P=N/A
- | Avastin (bevacizumab) / Roche
Trial completion: Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients (clinicaltrials.gov) - Sep 5, 2017
P2, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Phase classification: P2 --> P=N/A Recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Effectiveness of Antiretroviral Therapy During Acute HIV Infection (clinicaltrials.gov) - Aug 31, 2017
P1, N=25, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed Active, not recruiting --> Completed | N=36 --> 25 | Trial primary completion date: Jun 2014 --> Feb 2013
- | Trial completion, Enrollment change, Trial primary completion date: Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies (clinicaltrials.gov) - Aug 28, 2017
P=N/A, N=24, Completed, Sponsor: Lawson Health Research Institute
Active, not recruiting --> Completed | N=36 --> 25 | Trial primary completion date: Jun 2014 --> Feb 2013 Active, not recruiting --> Completed | N=30 --> 24 | Trial primary completion date: Aug 2008 --> Mar 2009
- | Trial completion: Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002 (clinicaltrials.gov) - Aug 22, 2017
P2, N=93, Completed, Sponsor: Barbara Ensoli, MD, PhD
Active, not recruiting --> Completed | N=30 --> 24 | Trial primary completion date: Aug 2008 --> Mar 2009 Active, not recruiting --> Completed
- | Trial primary completion date: Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand (clinicaltrials.gov) - Aug 21, 2017
P=N/A, N=2816, Active, not recruiting, Sponsor: Institut de Recherche pour le Developpement
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Sep 2020
- | Trial completion: Evaluation of Enhanced Syphilis Screening Among HIV-positive Men (clinicaltrials.gov) - Aug 18, 2017
P=N/A, N=3131, Completed, Sponsor: St. Michael's Hospital, Toronto
Trial primary completion date: Dec 2016 --> Sep 2020 Recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date: Transplantation and the Use of Raltegravir in HIV-Infected Patients (clinicaltrials.gov) - Aug 16, 2017
P=N/A, N=17, Completed, Sponsor: Duke University
Recruiting --> Completed Recruiting --> Completed | N=10 --> 17 | Trial primary completion date: Oct 2017 --> Jun 2017
- Trogarzo (ibalizumab IV) / Theratechnologies, TaiMed Biologics
Trial completion, Trial primary completion date: Investigator-Sponsored Protocol - Continued Use of Ibalizumab (clinicaltrials.gov) - Aug 16, 2017
P2, N=5, Completed, Sponsor: Kaiser Permanente
Recruiting --> Completed | N=10 --> 17 | Trial primary completion date: Oct 2017 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Dec 2016
- | Trial completion, Trial primary completion date, IO biomarker: Auto-HTAP: Auto-immunity and Pulmonary Arterial Hypertension (clinicaltrials.gov) - Aug 14, 2017
P=N/A, N=629, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jul 2014
- Trial primary completion date: Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression (clinicaltrials.gov) - Aug 11, 2017
P4, N=1, Terminated, Sponsor: The Cleveland Clinic
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jul 2014 Trial primary completion date: Mar 2016 --> Dec 2011
- | Enrollment change: Analysis of Genetic Factors Which May Influence the Course of HIV Infection (clinicaltrials.gov) - Aug 10, 2017
P=N/A, N=100, Completed, Sponsor: Deborah Rund
Trial primary completion date: Mar 2016 --> Dec 2011 N=150 --> 100
- || Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare
Trial primary completion date: TRIUMPH: Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany (clinicaltrials.gov) - Aug 9, 2017
P=N/A, N=400, Recruiting, Sponsor: ViiV Healthcare
N=150 --> 100 Trial primary completion date: Jul 2018 --> Oct 2018
- || emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial primary completion date: A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA (clinicaltrials.gov) - Aug 8, 2017
P=N/A, N=400, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Jul 2018 --> Oct 2018 Trial primary completion date: Jun 2017 --> Dec 2017
- | Isentress (raltegravir) / Merck (MSD)
Trial completion, Enrollment change: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Aug 7, 2017
P2, N=11, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Jun 2017 --> Dec 2017 Active, not recruiting --> Completed | N=100 --> 11
- | Enrollment closed, Enrollment change: Comparison of Two Intrauterine Devices (IUDs) Among Cape Town HIV-positive Women (clinicaltrials.gov) - Aug 2, 2017
P=N/A, N=166, Active, not recruiting, Sponsor: FHI 360
Active, not recruiting --> Completed | N=100 --> 11 Recruiting --> Active, not recruiting | N=288 --> 166
- ||| Phase classification, Enrollment change: Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients (clinicaltrials.gov) - Aug 1, 2017
P4, N=974, Completed, Sponsor: ViiV Healthcare
Recruiting --> Active, not recruiting | N=288 --> 166 Phase classification: P=N/A --> P4 | N=2469 --> 974
- | Stamaril (yellow fever vaccine) / Sanofi
Trial primary completion date: The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. (clinicaltrials.gov) - Jul 28, 2017
P3, N=71, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Phase classification: P=N/A --> P4 | N=2469 --> 974 Trial primary completion date: May 2017 --> Oct 2017
- ritonavir / Generic mfg.
Trial primary completion date, Combination therapy: Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects (clinicaltrials.gov) - Jul 28, 2017
P3, N=24, Terminated, Sponsor: ViiV Healthcare
Trial primary completion date: May 2017 --> Oct 2017 Trial primary completion date: Oct 2005 --> Sep 2007
- | Trial withdrawal: DANET1: Effect of Repeated Exposures to Compressed Air on Patients With AIDS (clinicaltrials.gov) - Jul 27, 2017
P2, N=0, Withdrawn, Sponsor: Designed Altobaric Technology, Incorporated
Trial primary completion date: Oct 2005 --> Sep 2007 Suspended --> Withdrawn
- ||||| Enrollment closed: PRINCE2: Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients (clinicaltrials.gov) - Jul 27, 2017
P3, N=167, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Suspended --> Withdrawn Completed --> Active, not recruiting
- | Isentress (raltegravir) / Merck (MSD)
Trial completion, Trial initiation date: STERAL: Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection (clinicaltrials.gov) - Jul 25, 2017
P4, N=45, Completed, Sponsor: Juan Mac
Completed --> Active, not recruiting Active, not recruiting --> Completed | Initiation date: Nov 2014 --> Feb 2014
- | Phase classification: Project HERMITAGE: HIV Prevention in Hospitalized Russian Drinkers (clinicaltrials.gov) - Jul 21, 2017
P=N/A, N=700, Completed, Sponsor: Boston Medical Center
Active, not recruiting --> Completed | Initiation date: Nov 2014 --> Feb 2014 Phase classification: P3 --> P=N/A
- ||||||| lamivudine / Generic mfg.
Trial completion, Head-to-Head: MOBIDIP: Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa (clinicaltrials.gov) - Jul 21, 2017
P3, N=265, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Phase classification: P3 --> P=N/A Active, not recruiting --> Completed
- Trial primary completion date, Gene therapy: Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have Received OZ1 Gene Therapy as Part of a Clinical Trial (clinicaltrials.gov) - Jul 13, 2017
P2, N=37, Active, not recruiting, Sponsor: Janssen-Cilag Pty Ltd
Active, not recruiting --> Completed Trial primary completion date: Dec 2020 --> Nov 2017
- | Biomarker, Trial completion, Enrollment change, Trial primary completion date: Impact of Antiretroviral Therapy on Cardiac Biomarkers (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=40, Completed, Sponsor: University of California, Davis
Trial primary completion date: Dec 2020 --> Nov 2017 Recruiting --> Completed | N=20 --> 40 | Trial primary completion date: Jan 2010 --> Oct 2014
- | nevirapine / Generic mfg.
Trial completion: Differences in Blood Levels of Nevirapine in HIV-infected Patients in Uganda and the United States (clinicaltrials.gov) - Jun 30, 2017
P4, N=24, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed | N=20 --> 40 | Trial primary completion date: Jan 2010 --> Oct 2014 Active, not recruiting --> Completed